Expression of CD44 variants and its association with survival in pancreatic cancer

被引:51
作者
Gotoda, T
Matsumura, Y
Kondo, H
Saitoh, D
Shimada, Y
Kosuge, T
Kanai, Y
Kakizoe, T
机构
[1] Natl Canc Ctr Hosp, Dept Internal Med, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr Hosp, Dept Surg, Chuo Ku, Tokyo 1040045, Japan
[3] Natl Canc Inst, Res Inst, Dept Pathol, Chuo Ku, Tokyo 1040045, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1998年 / 89卷 / 10期
关键词
CD44; variants; pancreatic cancer; metastasis; prognosis; immunohistochemistry;
D O I
10.1111/j.1349-7006.1998.tb00493.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the CD44 variant 6(v6) molecule has been noted as a marker for tumor metastasis and prognosis in several tumors, we examined whether or not v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. In addition, we attempted to assess the clinicopathological implications for pancreatic cancer of the variant 2 (v2) isoform using a recently developed monoclonal antibody against a v2 epitope, The expression of CD44 variants was evaluated immunohistochemically in paraffin-embedded pancreatic cancer tissues from 42 patients who were confirmed surgically and histologically to have received curative resection. An indirect immunoperoxidase method was used with monoclonal antibodies against epitopes of the standard (CD44s) portion, v6 and v2, Protein expression data were evaluated statistically for any correlations,vith the length of survival or with histological parameters. The expression of CD44v6 and v2 was observed only in tumor cells, if at all, On the other hand, expression of total CD44 (including CD44v, as well as CD44s) was observed in both tumors and adjacent normal sites, Tumor tissue from 21 (50%) and 16 (38%) patients showed positive immunoreactivity with mAb 2F10 (anti-CD44v6) and mAb M23.6.1 (anti-CD44v2), respectively, The expression of CD44v6 and v2 was correlated with decreased overall survival (P = 0.0160 and P = 0.0125, respectively). A significant correlation was obtained between CD44v2 peptide expression and vessel invasion (P = 0.026), These results suggest that CD44v2 and CD44v6 may be useful markers for poor prognosis in curatively resected primary pancreatic cancer.
引用
收藏
页码:1033 / 1040
页数:8
相关论文
共 38 条
[1]   PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44 [J].
ARCH, R ;
WIRTH, K ;
HOFMANN, M ;
PONTA, H ;
MATZKU, S ;
HERRLICH, P ;
ZOLLER, M .
SCIENCE, 1992, 257 (5070) :682-685
[2]   CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[3]  
BORGYA A, 1995, J CLIN PATHOL-CL MOL, V48, pM241
[4]   FACTORS INFLUENCING SURVIVAL AFTER PANCREATICODUODENECTOMY FOR PANCREATIC-CANCER [J].
CAMERON, JL ;
CRIST, DW ;
SITZMANN, JV ;
HRUBAN, RH ;
BOITNOTT, JK ;
SEIDLER, AJ ;
COLEMAN, J .
AMERICAN JOURNAL OF SURGERY, 1991, 161 (01) :120-125
[5]  
Castella EM, 1996, VIRCHOWS ARCH, V429, P191
[6]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279
[7]   CD44 - A NEW PROGNOSTIC MARKER FOR NEUROBLASTOMA [J].
FAVROT, MC ;
COMBARET, V ;
LASSET, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (26) :1965-1965
[8]   A HUMAN-LYMPHOCYTE HOMING RECEPTOR, THE HERMES ANTIGEN, IS RELATED TO CARTILAGE PROTEOGLYCAN CORE AND LINK PROTEINS [J].
GOLDSTEIN, LA ;
ZHOU, DFH ;
PICKER, LJ ;
MINTY, CN ;
BARGATZE, RF ;
DING, JF ;
BUTCHER, EC .
CELL, 1989, 56 (06) :1063-1072
[9]   A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS [J].
GUNTHERT, U ;
HOFMANN, M ;
RUDY, W ;
REBER, S ;
ZOLLER, M ;
HAUSSMANN, I ;
MATZKU, S ;
WENZEL, A ;
PONTA, H ;
HERRLICH, P .
CELL, 1991, 65 (01) :13-24
[10]   CD44 - A MOLECULE INVOLVED IN LEUKOCYTE ADHERENCE AND T-CELL ACTIVATION [J].
HAYNES, BF ;
TELEN, MJ ;
HALE, LP ;
DENNING, SM .
IMMUNOLOGY TODAY, 1989, 10 (12) :423-428